Chitosan – An alternative drug delivery approach for neurodegenerative diseases
Neurological disorders have become severe and dreadful issues around the globe that are rarely directly mediated because of the blood-brain barrier (BBB). Despite the various therapeutic strategies, including the utilization of cholinesterase inhibitors, metal chelators, molecular chaperones, and anti-body treatment that have been put forth, drug delivery to the brain has remained a problem in the treatment of neurodegenerative disorders (NDD). Chitosan, one of nature's multifunctional polymers, is acknowledged as a useful chemical in the medical and pharmaceutical industries due to its distinctive and flexible biological characteristics. By using Chitosan and its derivatives as drug delivery methods, it is possible to give medications in a sustained and regulated way, increase their stability, and lessen the likelihood of adverse drug reactions. In the current review, we have concentrated on the significance of Chitosan and its derivatives to become a hotspot in drug delivery, particularly for NDDs. This review also explains their properties as drug delivery vectors and their ability to cross the BBB, which is a significant obstacle to medication administration in NDDs. In conclusion, this review suggests that expanding the scope of such research would make it possible to develop NDD drug delivery systems that are more efficient..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Carbohydrate Polymer Technologies and Applications - 7(2024), Seite 100460- |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mahalaxmi Iyer [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Biochemistry |
|---|
| doi: |
10.1016/j.carpta.2024.100460 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ097019135 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ097019135 | ||
| 003 | DE-627 | ||
| 005 | 20240413170400.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240413s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.carpta.2024.100460 |2 doi | |
| 035 | |a (DE-627)DOAJ097019135 | ||
| 035 | |a (DE-599)DOAJf2f97cf34c614fcfb64ca4ccbc4e2f91 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a QD415-436 | |
| 100 | 0 | |a Mahalaxmi Iyer |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chitosan – An alternative drug delivery approach for neurodegenerative diseases |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Neurological disorders have become severe and dreadful issues around the globe that are rarely directly mediated because of the blood-brain barrier (BBB). Despite the various therapeutic strategies, including the utilization of cholinesterase inhibitors, metal chelators, molecular chaperones, and anti-body treatment that have been put forth, drug delivery to the brain has remained a problem in the treatment of neurodegenerative disorders (NDD). Chitosan, one of nature's multifunctional polymers, is acknowledged as a useful chemical in the medical and pharmaceutical industries due to its distinctive and flexible biological characteristics. By using Chitosan and its derivatives as drug delivery methods, it is possible to give medications in a sustained and regulated way, increase their stability, and lessen the likelihood of adverse drug reactions. In the current review, we have concentrated on the significance of Chitosan and its derivatives to become a hotspot in drug delivery, particularly for NDDs. This review also explains their properties as drug delivery vectors and their ability to cross the BBB, which is a significant obstacle to medication administration in NDDs. In conclusion, this review suggests that expanding the scope of such research would make it possible to develop NDD drug delivery systems that are more efficient. | ||
| 650 | 4 | |a Chitosan | |
| 650 | 4 | |a Neurodegenerative diseases | |
| 650 | 4 | |a Carbohydrate polymers | |
| 650 | 4 | |a Therapeutic approach | |
| 650 | 4 | |a Nanotechnology | |
| 653 | 0 | |a Biochemistry | |
| 700 | 0 | |a Ajay Elangovan |e verfasserin |4 aut | |
| 700 | 0 | |a Ramya Sennimalai |e verfasserin |4 aut | |
| 700 | 0 | |a Harysh Winster Suresh Babu |e verfasserin |4 aut | |
| 700 | 0 | |a Saranya Thiruvenkataswamy |e verfasserin |4 aut | |
| 700 | 0 | |a Jayalakshmi Krishnan |e verfasserin |4 aut | |
| 700 | 0 | |a Mukesh Kumar Yadav |e verfasserin |4 aut | |
| 700 | 0 | |a Abilash Valsala Gopalakrishnan |e verfasserin |4 aut | |
| 700 | 0 | |a Arul Narayanasamy |e verfasserin |4 aut | |
| 700 | 0 | |a Balachandar Vellingiri |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Carbohydrate Polymer Technologies and Applications |d Elsevier, 2021 |g 7(2024), Seite 100460- |w (DE-627)DOAJ07860947X |x 26668939 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2024 |g pages:100460- |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.carpta.2024.100460 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/f2f97cf34c614fcfb64ca4ccbc4e2f91 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S2666893924000409 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2666-8939 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2024 |h 100460- | ||